Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP982720priorityCriticalpatent/ECSP982720A/en
Publication of ECSP982720ApublicationCriticalpatent/ECSP982720A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Formulación que contiene un opioide en combinación con un agonista alfa-adenérgico o sales farmacéuticamente aplicables de las sustancias activas y otros excipientes, en que para el agonista alfa-adrenérgicos se utiliza la unidad de dosificación entre 1ug y 500ug, y para el opioide la unidad de dosificación entre 0.5 y 50 mg. evitando la formulación de efectos circulatorios de origen central, y la utilización como analgésico.Formulation containing an opioid in combination with an alpha-adrenergic agonist or pharmaceutically applicable salts of the active substances and other excipients, in which the dosage unit between 1ug and 500ug is used for the alpha-adrenergic agonist, and for the opioid unit dosage between 0.5 and 50 mg. avoiding the formulation of circulatory effects of central origin, and the use as an analgesic.
ECSP9827201998-10-301998-10-30
FORMULATION CONTAINING AN OPIOID IN COMBINATION WITH AN ADRENERGIC AGONIST AND ITS USE AS AN ANALGESIC
ECSP982720A
(en)
PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMBINATION OF METFORMIN AND FIBRATE AND ITS USE IN THE PREPARATION OF DRUGS INTENDED TO REDUCE HYPERGLYCEMIA.
Formulation suitable for subcutaneous administration comprising at least 100 mg / ml of ctlaig, a sugar, and a pharmaceutically stable aqueous carrier; article of manufacture comprising at least one container containing the aforementioned formulation. (divisional application n ° 3597-06)
Use of at least one compound selected from melatonin, melatoninergic agents, melatonin agonists and antagonists, in an amount of 0.0025-50 mg, to prepare a useful medicine for the treatment and improvement of the restorative quality of sleep.